Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2018
- Current Ratio since 2018
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
Feb 24, 2023 | = | ÷ | = | ÷ | |||||||
Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
Mar 13, 2019 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Moderna Inc. Annual Report.
Comparison to Competitors
Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 23, 2024 | ||||||||||||
Feb 24, 2023 | ||||||||||||
Feb 25, 2022 | ||||||||||||
Feb 26, 2021 | ||||||||||||
Feb 27, 2020 | ||||||||||||
Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 23, 2024 | ||
Feb 24, 2023 | ||
Feb 25, 2022 | ||
Feb 26, 2021 | ||
Feb 27, 2020 | ||
Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc. | Health Care | |
---|---|---|
Feb 23, 2024 | ||
Feb 24, 2023 | ||
Feb 25, 2022 | ||
Feb 26, 2021 | ||
Feb 27, 2020 | ||
Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).